	US 11,964,016 B2
	Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
Seblewongel Asrat, New York, NY (US); Andre Limnander, New York, NY (US); Jamie Orengo, Cortlandt Manor, NY (US); Andrew J. Murphy, Croton-on-Hudson, NY (US); and George D. Yancopoulos, Yorktown Heights, NY (US)
Assigned to REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed by REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed on Mar. 20, 2020, as Appl. No. 16/825,955.
Claims priority of provisional application 62/957,550, filed on Jan. 6, 2020.
Claims priority of provisional application 62/822,022, filed on Mar. 21, 2019.
Prior Publication US 2020/0345843 A1, Nov. 5, 2020
Int. Cl. A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61P 37/08 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/3955 (2013.01) [A61P 37/08 (2018.01); A61K 2039/507 (2013.01)]

99 Claims

1. A method of reducing or eliminating allergen-specific serum IgE in a subject, comprising: (a) selecting a subject with an allergic disease or disorder, a mast cell activation disorder or mastocytosis; and (b) administering to the subject in need thereof a therapeutically effective amount of an IL-4/IL-13 pathway inhibitor and a plasma cell ablating agent, wherein the plasma cell ablating agent is an anti-BCMA/anti-CD3 bispecific antibody or antigen-binding fragment thereof comprising (i) a first antigen-binding domain that specifically binds to BCMA; and (ii) a second antigen-binding domain that specifically binds CD3.